Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-24T07:27:50.283Z Has data issue: false hasContentIssue false

Indices of fatty acid desaturase activity in healthy human subjects: effects of different types of dietary fat

Published online by Cambridge University Press:  18 February 2013

Bengt Vessby*
Affiliation:
Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala Science Park, SE-751 85Uppsala, Sweden
Inga-Britt Gustafsson
Affiliation:
Culinary Art and Meal Science, School of Hospitality, Örebro University, Grythyttan, Sweden
Siv Tengblad
Affiliation:
Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala Science Park, SE-751 85Uppsala, Sweden
Lars Berglund
Affiliation:
Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden
*
*Corresponding author: B. Vessby, fax +46 18 6117976, email [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Δ9-Desaturase (stearoyl-CoA desaturase 1, SCD-1) regulates the desaturation of SFA, mainly stearic and palmitic, to MUFA. Δ6-Desaturase (D6D) and Δ5-desaturase (D5D) are involved in the metabolism of linoleic and α-linolenic acid to polyunsaturated metabolites. The objective of the present study was to study the effects of different types of dietary fat on indices of fatty acid desaturase (FADS) activity (evaluated as product:precursor ratios) in plasma and skeletal muscle in human subjects. A high SCD-1 index has been related to obesity and metabolic disorders, while the D5D index is associated with insulin sensitivity. Fatty acid composition of serum and skeletal muscle lipids was analysed by GLC during a randomised, controlled, 3-month dietary intervention in healthy subjects. A comparison of the effects of a diet containing butter fat (SFA, n 17) with a diet containing monounsaturated fat (MUFA, n 17), keeping all other dietary components constant, showed a reduced SCD-1 activity index by 20 % on the MUFA diet compared with the SFA diet assessed in serum cholesteryl esters. The D6D and D5D indices remained unaffected. Supplementation with long-chain n-3 fatty acids reduced the SCD-1 index by a similar magnitude while the D6D index decreased and the D5D index increased. It is concluded that changes in the type of fat in the diet affect the indices of FADS activity in serum and skeletal muscle in human subjects. The desaturase activity indices estimated from the serum lipid ester composition are significantly related to corresponding indices studied in skeletal muscle phospholipids.

Type
Full Papers
Copyright
Copyright © The Authors 2013 

The fatty acid composition of the diet is one important determinant of the health effects of food. A low proportion of unsaturated fat and a high proportion of saturated fat in the diet have been related to an increased risk for atherosclerotic CVD(Reference Schaefer1) and diabetes(Reference Feskens2). The assessment of fat intake from different food sources is, however, associated with substantial measurement errors. The fatty acid composition of the diet is reflected in the fatty acid composition of body tissues, and analysis of the plasma fatty acid composition is probably a more objective and accurate way to mirror dietary fat quality(Reference Arab3, Reference Baylin and Campos4).

Not only the content of fatty acids in the diet, but also the endogenous metabolism of fatty acids, e.g. by elongation and desaturation, will influence their effects in the body(Reference Nakamura and Nara5, Reference Ntambi and Miyazaki6). Δ9-Desaturase (stearoyl-CoA desaturase 1, SCD-1) activity has an important role in modulating the intracellular effects of SFA, as demonstrated in vitro in human adipocytes(Reference Collins, Neville and Hoppa7) and myotubes(Reference Peter, Weigert and Staiger8). A high SCD-1 activity index has been associated with obesity(Reference Pan, Lilloja and Milner9Reference Warensjö, Rosell and Hellenius11), hypertriacylglycerolaemia(Reference Paillard, Catheline and Duff12) and the metabolic syndrome(Reference Warensjö, Riserus and Vessby13), as well as with an increased risk to develop insulin resistance(Reference Risérus, Ärnlöv and Berglund14) and cardiovascular death and total death(Reference Warensjö, Sundström and Vessby15). In contrast, the Δ5-desaturase (D5D) index in serum(Reference Murakami, Sasaki and Takahashi10, Reference Warensjö, Rosell and Hellenius11) and skeletal muscle(Reference Pan, Lilloja and Milner9) is associated with insulin sensitivity. A high D5D index in serum predicts a reduced risk to develop the metabolic syndrome(Reference Warensjö, Riserus and Vessby13) and total as well as cardiovascular death(Reference Warensjö, Sundström and Vessby15).

Much of our knowledge regarding the nutritional regulation of fatty acid desaturases (FADS) is derived from experimental studies in animal models, while information from human studies is sparse. The aim of the present study was to investigate how a change in dietary fat quality only, keeping all other aspects of the diet unchanged, influences the indices of FADS activity in human serum lipids and skeletal muscle tissue. To measure mRNA or protein expression of these enzymes in human tissues in a clinical study is not readily performed. We have studied the relationships (ratios) between fatty acid products and precursors in lipid esters in serum and skeletal muscle tissue to estimate the enzyme activities. There are animal studies, in vitro data(Reference Miyazaki, Man and Ntambi16Reference Chu, Miyazaki and Man20) as well as human studies(Reference Riserus, Tan and Fielding21Reference Peter, Cegan and Wagner24) supporting the assumption that these ratios may be used as indices of actual SCD-1 gene expression. However, the ratios cannot be assumed to directly reflect desaturase activities. The rationale for using product:precursor ratios in tissue and blood lipids to reflect SCD-1 activity has recently been reviewed(Reference Hodson and Fielding25). Polymorphisms in the genes FADS1 and FADS2, encoding D5D and Δ6-desaturase (D6D), respectively, are associated with the ratios of arachidonic acid (20 : 4n-6) to linoleic acid (18 : 2n-6) and EPA (20 : 5n-3) to α-linolenic acid (18 : 3n-3) in erythrocyte membranes(Reference Martinelli, Girelli and Malerba26), with the fatty acid composition in serum phospholipids (PL)(Reference Malerba, Schaeffer and Xumerle27) and with plasma fatty acids(Reference Merino, Johnston and Clarke28). They are also associated with fatty acid profiles in erythrocytes, reflecting altered D5D and D6D activities evaluated as product:precursor ratios(Reference Zietemann, Kröger and Enzenbach29).

The present study concerns the effects of a diet based on butter fat compared with a diet containing monounsaturated fat, as well as the effects of the addition of long-chain n-3 fatty acids on the indices of SCD-1, D5D and D6D activities in serum lipid esters and skeletal muscle lipids in healthy human subjects. The main interest concerned the comparison between a diet rich in butter fat and a diet containing MUFA. The hypothesis was that the butter-rich diet would induce a higher SCD-1 activity index than the diet containing monounsaturated fat.

Materials and methods

Design of the study

For the studies of the effects of dietary fat on desaturase activities, we have used earlier findings (B Vessby, I-B Gustafsson, S Tengblad and L Berglund, unpublished results) from the KANWU study(Reference Vessby, Uusitupa and Hermansen30), a controlled parallel study lasting 90 d. The study design and methods have been described in detail earlier(Reference Vessby, Uusitupa and Hermansen30). Participants were randomly allocated to a butter-rich diet containing a high proportion of SFA (SFA diet) or to a diet containing MUFA (MUFA diet) due to a high content of oleic acid. Within the groups, there was a second random assignment to supplements of capsules containing fish oil (3·6 g n-3 fatty acids/d containing 2·4 g EPA and DHA, i.e. three capsules twice per d of Pikasol; Lube A/S) or placebo capsules containing the same amount of olive oil. The test period was preceded by a 2-week ‘stabilisation period’ on the habitual diet when all subjects received placebo capsules. Clinical tests were carried out during this period and participants completed a 3 d dietary record (two weekdays and one weekend day) to document pretrial dietary habits. In addition, two 3 d dietary records were completed at the beginning of the second and third months of the study period.

Subjects

The present study is restricted to the Swedish arm of the KANWU study, performed at Uppsala University, including twenty-seven men and seven women. Table 1 presents the clinical characteristics of the study subjects. Subjects with impaired glucose tolerance were included but those with diabetes were excluded. The degree of physical activity and alcohol intake did not change throughout the study. Subjects using lipid-lowering drugs, thiazide diuretics, β-blockers and corticosteroids were excluded. The present study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the Ethics Committee at the Medical Faculty of Uppsala University. Verbal informed consent was obtained from all subjects. Verbal consent was witnessed and formally recorded.

Table 1 Clinical characteristics of the participants (Mean values and standard deviations, n 34)

SBP, systolic blood pressure; DBP, diastolic blood pressure; P, plasma; S, serum.

Diets

Participants were instructed to eat isoenergetic diets, with the same proportions of the main nutrients including similar amounts of total fat, but with a high proportion of SFA (SFA diet) or MUFA (MUFA diet). The diets were calculated to contain 37 % energy (E%) of fat with 17, 14 and 6 E% of SFA, MUFA and PUFA, respectively, in the SFA diet and 8, 23 and 6 E% in the MUFA diet using the database from the Swedish Food Administration. The estimated proportion of trans-fatty acids was low and similar in both diets. All participants were instructed before the study by trained dietitians on the preparation of their diets, with repeated contacts every second week thereafter to assure good adherence to the diet. They were all supplied with main dishes prepared to contain either mainly saturated or monounsaturated fat and edible fats to be used as spreads on bread, for cooking and in dressings. Core foods such as butter, margarine, oils and a range of other staple items were provided. Subjects were not informed about the type of diet they were following. The SFA diet included butter and table margarine containing a relatively high proportion of SFA. The MUFA diet included a spread and margarine containing high proportions of oleic acid derived from high-oleic sunflower oil with negligible amounts of trans-fatty acids and n-3 fatty acids.

The intake during the test period was calculated as the mean values of the dietary records provided during the second and third months of the study. Data on margarines and other specially prepared foods were entered onto the database for inclusion in the analyses. Serum lipid fatty acid composition was measured to confirm the validity of the reported dietary fatty acid intake.

Clinical tests and laboratory analyses

Blood samples were drawn after a 12 h overnight fast from an antecubital vein. A number of clinical tests and analyses were performed before and at the end of the study. In the Uppsala cohort, a skeletal muscle biopsy was performed at day 90 for determination of the fatty acid composition in the skeletal muscle tissue. A muscle sample was obtained from the musculus quadriceps femoris (vastus lateralis) by an incision through the skin and fascia from the mid-lateral part of the muscle under local anaesthesia using a Bergstrom needle(Reference Bergstrom31), and then immediately frozen and stored at − 70°C until analysis. Thereafter, one part of the sample (15–30 mg) was homogenised, extracted overnight and separated by TLC for analysis of the fatty acid composition.

The fatty acid composition of serum and skeletal muscle lipids was determined by GLC, after separation of the fatty acid fractions by TLC, using a 25 m NB-351 silica capillary column, essentially as described earlier(Reference Boberg, Croon and Gustafsson32). For plasma fatty acids, the CV between successive GC runs was 0·2–5 %. For determination of the proportions of fatty acids in skeletal muscle PL, based on duplicate samples, the CV was less than 10 % for all the fatty acids with the exception of palmitoleic acid (16 : 1n-7), heptadecanoic acid (17 : 0) and α-linolenic acid (18 : 3n-3), which were present in small amounts with larger variations between the analyses (CV 20, 28 and 44 %, respectively). For the proportions of fatty acids in skeletal muscle TAG, the CV was 10 % or less for all fatty acids with proportions larger than 0·5 % with the exception of α-linolenic acid (CV 13 %). The relative amount of fatty acids was expressed as a percentage of the total amount of fatty acids reported.

To estimate the desaturase activities, we used the product:precursor ratios of individual fatty acids in lipid esters according to the following: Δ9-desaturase (SCD-1) activity index, 16 : 1n-7/16 : 0 or 18 : 1/18 : 0 (see below); D6D activity index, 18 : 3n-6/18 : 2n-6 (or 20 : 3n-6/18 : 2n-6 in PL due to a very low proportion of 18 : 3n-6); D5D activity index, 20 : 4n-6/20 : 3n-6.

Statistical methods

Results for continuous variables are presented as means and standard variations. For variables with a skewed distribution, a logarithmic transformation was made before the statistical analysis. For each outcome variable, treatment effects were estimated from a statistical model in which treatment categories (SFA diet/MUFA diet and the presence/absence of n-3 fatty acids) and their interactions were analysed. Factors including age, sex and the baseline value of the outcome variable were considered as covariates. For outcome variables where the interaction between the analysed factors and the presence or absence of n-3 fatty acids was non-significant, a limited model was used excluding those terms. Results of the analyses are presented as adjusted mean treatment effects within groups and their P values. Furthermore, the difference between the treatment groups for adjusted mean treatment effects is presented. Due to the large number of statistical tests performed, P< 0·01 was chosen for statistical significance to reduce the risk for false mass significances.

Results

Clinical characteristics

The clinical characteristics of the participants randomised to the SFA and MUFA diets were closely similar, as were the characteristics of those randomised to supplementation with n-3 fatty acids (Pikasol) and placebo (Table S1, available online). Body weight remained unchanged during the study.

Diet composition

The only significant difference between the two diets concerned the content of SFA (17·6 E% on the SFA diet and 9·2 E% on the MUFA diet) and MUFA (10·3 and 19·5 E%, respectively), which were close to the targeted values, and cholesterol which was higher in the SFA diet. Importantly, the proportions of other nutrients were similar during the two dietary periods, including the amount of total fat and the proportion of PUFA (Table S2, available online). This was also true for the choice of foods in the diets during the test periods, including the type of carbohydrate-rich foods, with an identical content of dietary fibre. The nutrient composition of the diets of the subjects randomised to achieve n-3 fatty acids (Pikasol) and placebo capsules was close to identical (Table S3, available online).

Fatty acid composition in serum

Fatty acid compositions in serum in the SFA and MUFA groups were similar before the test periods (Table S4, available online) as were those of subjects randomised to supplementation with n-3 fatty acids or placebo (Table S5, available online).

There was an expected reduction in the proportion of most SFA after the MUFA period compared with the SFA period in both cholesteryl esters (CE) and PL (Table S4, available online). The exception was stearic acid (18 : 0), which remained unchanged. During the MUFA diet, there was a substantial increase in oleic acid (18 : 1) in both CE and PL (P< 0·0001). Although the difference in changes in palmitic acid (16 : 0) in serum during the two periods was not clearly seen in CE (P= 0·03, NS), these changes were significantly different in PL (P= 0·0009). A clear difference regarding the changes in palmitoleic acid (16 : 1n-7) (which decreased on the MUFA diet) was seen in CE (P= 0·002). This difference was not significant in PL. There was a difference between the changes in linoleic acid during the SFA and MUFA periods in CE (P= 0·009) with a certain decrease during the MUFA period compared with the SFA period. Such a difference was not apparent in PL. There were no differences between the two periods regarding all long-chain PUFA with the exception of an increase in docosapentaenoic acid (22 : 5n-3) in PL during the SFA period, which significantly differed from that during the MUFA period (P= 0·002).

Supplementation with n-3 fatty acids caused no significant changes in any SFA or MUFA in serum CE (Table S5, available online). In PL, there was, on the other hand, a significant increase in stearic acid (P= 0·009) and a clear reduction in oleic acid (P< 0·0001) after supplementation with n-3 fatty acids compared with placebo. Linoleic acid levels were reduced in both CE (P< 0·0001) and PL (P< 0·0001). The proportions of dihomo-γ-linolenic acid (20 : 3n-6) were reduced in both CE and PL, while arachidonic acid (20 : 4n-6) was significantly reduced only in PL (P< 0·0001). All long-chain n-3 fatty acids increased during Pikasol supplementation as expected (P< 0·0001 for all).

Effects of dietary fat changes on desaturase indices in serum

Tables 2 and 3 show the FADS indices estimated from the CE and PL fatty acid compositions in serum before the diet periods, respectively, and the changes in indices during the test periods as related to the changes in dietary fat quality. There was a significantly reduced SCD-1 index (P= 0·009), as mirrored by the ratio 16 : 1n-7 to 16 : 0 in CE, by 20 % on the MUFA diet compared with the SFA diet (Table 2). The difference was not significant when analysing PL. An increase in 18 : 1 to 18 : 0 during the MUFA diet seen in both CE and PL was, on the other hand, directly related to the high proportion of oleic acid in the MUFA diet and cannot be related to SCD-1 activity. There was no indication of any changes in the D6D or D5D index due to the different fat types in the SFA and MUFA diets.

Table 2 Fatty acid desaturase activities estimated from the serum cholesteryl ester (CE) and phospholipid (PL) fatty acid compositions in subjects randomised to the SFA (n 17) and MUFA (n 17) diets, respectively* (Mean values and standard deviations)

* Treatment effects were estimated from a statistical model in which treatment categories (SFA diet/MUFA diet and the presence/absence of n-3 fatty acids) and their interactions were analysed.

Table 3 Fatty acid desaturase activities estimated from the serum cholesteryl ester (CE) and phospholipid (PL) fatty acid compositions in subjects randomised to supplementation with Pikasol (3·4 g/d) (n 17) or placebo (n 17), respectively* (Mean values and standard deviations)

* Treatment effects were estimated from a statistical model in which treatment categories (SFA diet/MUFA diet and the presence/absence of n-3 fatty acids) and their interactions were analysed.

Supplementation with long-chain n-3 fatty acids (Table 3) caused significant changes in the indices of SCD-1, D6D and D5D activities in both serum CE and PL. A reduction in the SCD-1 index during n-3 supplementation, compared with the placebo period, was seen as a significant lowering of the ratio 16 : 1n-7 to 16 : 0 (in CE) and 18 : 1 to 18 : 0 (in PL). Here, the ratio 18 : 1 to 18 : 0 could be considered to reflect SCD-1 activity, as oleic acid intake in the diet did not differ between the groups. The magnitude of the reduction in the SCD-1 index during Pikasol supplementation, compared with placebo, was similar to that on the MUFA diet when compared with the SFA diet. In addition, there was a significant decrease in the D6D index and an increase in the D5D index due to the addition of n-3 seen in both CE and PL.

Fatty acid composition in skeletal muscle

Skeletal muscle PL after the SFA diet showed a similar scenario to that in serum lipid esters with significantly higher 14 : 0 (P< 0·0001), 15 : 0 (P< 0·0002) and 17 : 0 (P< 0·0001) compared with the MUFA diet, while palmitic and stearic acids were not significantly different (Table S6, available online). The concentration of 16 : 1n-7 was significantly higher after the SFA diet (P= 0·002), while 18 : 1, due to high dietary intake, was higher after the MUFA period. With the exception of a higher concentration of 22 : 5n-3 after the SFA diet (P= 0·002), there were no significant differences between the two diets regarding all the PUFA. Similar differences between the two diets were seen in skeletal muscle TAG (Table S7, available online) regarding 14 : 0, 16 : 1n-7 and 18 : 1. In addition, palmitic acid (P= 0·008) was significantly higher in skeletal muscle TAG after the SFA diet compared with the MUFA diet.

Supplementation with n-3 fatty acids (Table S7, available online) caused a significant reduction in oleic acid and all n-6 PUFA in skeletal muscle PL, while the proportions of long-chain n-3 fatty acids increased (all P< 0·0001). The only effect of Pikasol seen in skeletal muscle TAG was a significant increase in the proportions of 22 : 5n-3 (P= 0·0007) and 22 : 6n-3 (P= 0·0002).

Effects of dietary fat changes on desaturase indices in skeletal muscle fatty acids

The desaturase indices studied in skeletal muscle PL after the test periods are shown in Table 4. The SCD-1 index, as estimated from the ratio between 16 : 1n-7 and 16 : 0, was significantly different when comparing the SFA and MUFA diets (higher after the SFA diet). Again, the higher 18 : 1 to 18 : 0 ratio on the MUFA diet is ascribed to the dietary intake of 18 : 1. No diverging effects of SFA and MUFA were seen on the D6D and D5D indices. Long-chain n-3 fatty acids reduced the SCD-1 index, demonstrated by a significantly reduced ratio between 18 : 1 and 18 : 0 in PL. The same tendency (NS) was seen for the ratio 16 : 1n-7 to 16 : 0. There was a significant reduction in D6D while the D5D index increased, in accordance with the changes seen in serum. Neither diet affected the desaturase indices calculated from the skeletal muscle TAG fatty acid compositions.

Table 4 Indices of fatty acid desaturase activities in skeletal muscle phospholipids (PL) and TAG after the change in dietary fat type (SFA v. MUFA) and supplementation with Pikasol (3·4 g/d) or placebo, respectively* (Mean values and standard deviations)

* Treatment effects were estimated from a statistical model in which treatment categories (SFA diet/MUFA diet and the presence/absence of n-3 fatty acids) and their interactions were analysed.

Associations between the desaturase indices estimated from serum lipid ester and skeletal muscle phospholipid fatty acid compositions

There were strong associations between the desaturase indices estimated from the fatty acid composition of serum lipids at the end of the intervention period and corresponding indices calculated from the skeletal muscle PL. Thus, there were positive correlations between the SCD-1 index assessed in serum CE and PL, on the one hand, and the corresponding index in skeletal muscle PL, on the other hand (r 0·58, P< 0·001 and r 0·56, P< 0·01, respectively). The ratio 16 : 1n-7 to 16 : 0 in CE and PL was also strongly associated with the D6D index (r 0·59, P< 0·001 and r 0·55, P< 0·01, respectively) and the D5D index (r − 0·51, P< 0·01 and r − 0·53, P< 0·01) as mirrored in skeletal muscle PL. The D6D activity index assessed in serum CE and PL was closely correlated with the D6D index in skeletal muscle PL (r 0·65, P< 0·001 and r 0·80, P< 0·001, respectively), as was the D5D index in both serum CE and PL with the D5D index in skeletal muscle PL (r 0·78, P< 0·001 and r 0·81, P< 0·001, respectively).

Discussion

The present study investigates the effects of the changes in dietary fat quality on the indices of FADS activities (product:precursor ratios), estimated in serum lipids and skeletal muscle, in healthy subjects. FADS are important regulators of the endogenous metabolism of fatty acids, derived from exogenous as well as endogenous sources(Reference Nakamura and Nara5, Reference Ntambi and Miyazaki6, Reference Mauvoisin and Mounier33). Δ9-Desaturase (SCD-1) regulates the desaturation of SFA, mainly stearic (18 : 0) and palmitic (16 : 0) acid, to the corresponding MUFA, by introducing a double bond in the Δ9 position. D6D and D5D regulate the desaturation of linoleic acid (18 : 2n-6) and α-linolenic acid (18 : 3n-3) to their polyunsaturated metabolites of the n-6 and n-3 series.

The desaturases are widely expressed in many tissues in the body including liver, skeletal muscle, adipose tissue, skin and the pancreatic β-cell. The expression of desaturase activities is regulated by a number of different nutrients including fatty acids, hormones and environmental factors as reviewed elsewhere(Reference Nakamura and Nara5, Reference Ntambi and Miyazaki6, Reference Hodson and Fielding25, Reference Mauvoisin and Mounier33). While PUFA are known to influence desaturase activities, there is little information, if any, directly comparing the effects of dietary fats rich in SFA and MUFA in human subjects. In the present study, we compared the effects on the indices of desaturase activities of a diet containing butter, with a high proportion of SFA and more cholesterol, with those of a diet rich in monounsaturated oleic acid. The proportions of PUFA in the diets were the same. In addition, we recorded the consequences of supplementation with long-chain n-3 PUFA.

In healthy human subjects on a high-fat diet, the majority of SFA in body tissues are derived from the diet, while net de novo lipogenesis is restricted(Reference Hellerstein34Reference Parks36). The major MUFA in plasma, oleic (18 : 1n-9) and palmitoleic (16 : 1n-7) acids, may either come from food or be formed in the body through the action of SCD-1. The content of 16 : 1n-7 is usually low in the diet with small variations. The only known major dietary source of 16 : 1n-7 is macadamia nuts, while other nuts are shown to be rich sources of 18 : 1 with a very low content of 16 : 1n-7(Reference Maguire, OÇSullivan and Galvin37). Macadamia nuts were not included, and minor dietary sources of 16 : 1n-7, e.g. fatty fish, were identical in both diets. This means that the proportion of 16 : 1n-7, when related to 16 : 0, may be considered to reflect SCD-1 activity(Reference Hodson and Fielding25). Oleic acid (18 : 1), on the other hand, is mostly not a useful indicator of SCD-1 activity as the Western diet contains considerable, and variable, amounts of oleic acid. The enrichment of monounsaturated fat in the MUFA diet in the present study was achieved by the inclusion of spreads, oils and margarines with a high content of oleic acid.

In the present study, the comparison between two diets rich in SFA and MUFA, respectively, showed that a diet containing a high proportion of butter fat, compared with a diet rich in monounsaturated oleic acid, was accompanied by a higher SCD-1 activity index as estimated from the serum lipid ester fatty acid composition (Table 2). The D6D and D5D indices remained unchanged. Suppression of SCD by dietary fat is unique to n-6 and n-3 PUFA(Reference Nakamura and Nara5, Reference Hodson and Fielding25, Reference Mauvoisin and Mounier33). Oleic acid has no effect on SCD-1 expression or protein levels(Reference Bené, Lasky and Ntambi38). Experimental studies have shown that SCD-1 mediates the pro-lipogenic effects of SFA in the diet(Reference Sampath, Miyazaki and Dobrzyn39). SFA induce an increase in SCD-1 mRNA levels in mice(Reference Sampath and Ntambi40) and palmitate increases SCD-1 expression in cultured myotubes(Reference Peter, Weigert and Staiger8). Rodent models indicate that SCD-1 activity is up-regulated in skeletal muscle cells, under conditions of saturated fat exposition, or in obesity(Reference Pinnamaneni, Southgate and Febbraio41). It has been suggested that SCD-1 has an important role in modulating the intracellular effects of SFA by converting them to less harmful MUFA(Reference Collins, Neville and Hoppa7, Reference Peter, Weigert and Staiger8). Thus, a high SCD-1 activity index in plasma may probably be considered as a reflection of high exposure to (exogenously or endogenously synthesised) saturated fat. This is compatible with the associations with obesity(Reference Pan, Lilloja and Milner9Reference Warensjö, Rosell and Hellenius11), hypertriacylglycerolaemia(Reference Paillard, Catheline and Duff12) and the metabolic syndrome(Reference Warensjö, Riserus and Vessby13), as well as with an increased risk to develop insulin resistance(Reference Risérus, Ärnlöv and Berglund14) and cardiovascular death(Reference Warensjö, Sundström and Vessby15). A high D5D activity index in skeletal muscle(Reference Pan, Lilloja and Milner9) and serum(Reference Murakami, Sasaki and Takahashi10, Reference Warensjö, Rosell and Hellenius11), on the other hand, is associated with good insulin sensitivity and a reduced risk to develop the metabolic syndrome(Reference Miyazaki, Man and Ntambi16) and cardiovascular death(Reference Warensjö, Sundström and Vessby15). An extensive review of the evidence for SCD and the risk of disease has recently been published(Reference Hodson and Fielding25).

SFA could mediate their effects on the SCD-1 promoter by directly increasing sterol regulatory element-binding protein (SREBP)-1c expression, or increasing the expression of peroxisome proliferator-activated receptor-γ coactivator-1β (PGC1-β), a SREBP-1c co-activator(Reference Lin, Yang and Tarr42). In addition, it is possible that the higher content of cholesterol in the SFA diet may have contributed to the increased SCD-1 activity, by opposing the repression of the gene mediated by PUFA, by a SREBP-1-independent mechanism(Reference Kim, Miyazaki and Ntambi43). Supplementation with long-chain n-3 fatty acids (Table 3) reduced the D6D index and increased the D5D activity index, in addition to a decrease in the SCD-1 index. Stable isotope studies in human subjects(Reference Pawlosky, Hibbeln and Lin44, Reference Hussein, Ah-Sing and Wilkinson45) have indicated a feedback control of D6D by dietary long-chain n-3 fatty acids. A transcriptional suppression of SCD-1 and D6D by dietary factors has been ascribed to long-chain PUFA of the n-6 and n-3 series, probably through the suppressed activity of SREBP-1c(Reference Nakamura and Nara5). Experimental studies have indicated that both D6D and D5D are suppressed by dietary PUFA(Reference Nakamura and Nara5). Whether the increase in the D5D index in the present study reflects a true increase in enzyme activity, or rather is a consequence of a reduced availability of the substrate due to the suppression of D6D activity, remains to be clarified.

Similar effects on the desaturase indices were seen not only in serum CE and PL, but also in skeletal muscle PL (Table 4). Associations between the indices of desaturase activities in serum lipid esters and in skeletal muscle PL were strong and highly significant. It suggests that estimations of the effects of dietary fat on desaturase activity indices in plasma lipids may closely reflect the effects on desaturase indices in other body tissues, as shown here for skeletal muscle. This is of practical importance as serum or plasma is readily available, while more invasive techniques are needed to obtain samples from other body tissues.

If the desaturation index is used to estimate enzyme activity, it should preferentially be used in defined lipid fractions(Reference Peter, Cegan and Wagner24, Reference Hodson and Fielding25, Reference Karpe and Hodson46). The specificity of PL and CE biosynthesis will have an important impact on the interpretation of fatty acid ratios as markers of fatty acid desaturation. Each hepatic lipid fraction has a characteristic fatty acid ratio(Reference Peter, Cegan and Wagner24). Comparing the SCD-1 activity index 16 : 1/16 : 0 in hepatic lipid fractions with hepatic SCD-1 mRNA expression showed strong associations with the SCD-1 activity indices of hepatic TAG, NEFA, CE and PL. The relationships to the 18 : 1/18 : 0 index were weaker or absent(Reference Peter, Cegan and Wagner23). A high ratio between 16 : 1n-7 and 16 : 0 in serum CE presumably mainly reflects a high SCD-1 activity index in the liver. Changes in the SCD-1 index in serum cholesterol esters were closely associated with a reduction in liver fat on a PUFA-rich diet(Reference Bjermo, Iggman and Kullberg47). In the present study, changes in the ratio 16 : 1n-7 to 16 : 0 were more clearly seen in serum CE than in PL, probably at least partly explained by higher levels and less variation in the proportions of 16 : 1n-7 in CE. It has been suggested(Reference Hodson and Fielding25) that plasma PL, which reflect a number of lipid pools, may be less useful as a biomarker of SCD-1 activity.

Changes in SCD-1 activity in adipose tissue, e.g. related to increased neolipogenesis(Reference Collins, Neville and Hoppa7), may, on the other hand, probably preferentially be studied in fasting plasma NEFA(Reference Warensjö, Rosell and Hellenius11) when adipose tissue samples are not at hand. SCD-1 activity in adipocytes(Reference Collins, Neville and Hoppa7) and skeletal muscle cells(Reference Peter, Weigert and Staiger8) is positively associated with insulin sensitivity. Accordingly, a high proportion of 16 : 1n-7 in plasma NEFA mirroring a high SCD-1 activity index in adipose tissue may be directly related to insulin sensitivity(Reference Stefan, Kantarzis and Celebi48).

The present study indicates that an increased intake of butter fat rich in SFA and cholesterol, when exchanged for oleic acid rich in MUFA, in human subjects is also associated with a higher SCD-1 activity index – when other components of the diet are kept unchanged. An alternative cause of increased SCD-1 activity is de novo lipogenesis from carbohydrates in the liver due to an excessive intake of sugar and refined carbohydrates(Reference Hudgins, Hellerstein and Seidman49, Reference Chong, Hodson and Bickerton50). In the present study, however, the amount of carbohydrates, as well as the type of carbohydrate-rich foods, was the same during the test periods.

There is a sex-specific effect on SCD-1 expression, and the ratio 16 : 1 to 16 : 0 in CE seems to be higher in women than in men(Reference Hodson and Fielding25). In the present study, men and women were randomly divided into the two intervention groups (Table S1, available online). The small number of women included does not allow a study of possible sex differences in response to the changes in the type of dietary fat, but sex is used as a covariate in the statistical analyses. Induction of SCD-1 is insulin responsive(Reference Nakamura and Nara5, Reference Hodson and Fielding25). Metabolic variables, including fasting insulin and insulin sensitivity index, were well comparable in the intervention groups (Table S1, available online). In order to reduce the risk that different levels before the intervention (e.g. due to insulin resistance) would confound the results, baseline values of the outcome variables have been used as covariates in the statistical analyses. The desaturase indices in the two groups before the intervention were closely similar (Tables 2 and 3).

Studies of the indices of FADS activity are of value to understand how fatty acid metabolism and related health effects are influenced by exogenous as well as endogenous factors. This is, as far as we know, the first controlled study in human subjects where a comparison of the effects of a diet based on butter fat with a diet containing monounsaturated fat, keeping all other dietary components constant, shows a higher SCD-1 activity index on a diet rich in butter fat than on a diet containing monounsaturated fat. This was apparent when assessed in serum lipid esters as well as in skeletal muscle PL. The indices of D6D and D5D activities remained unaffected. Supplementation with long-chain n-3 fatty acids also showed, in addition to a reduced SCD-1 index, a lower D6D activity index and a significantly increased D5D activity index.

Supplementary material

To view supplementary material for this article, please visit http://dx.doi.org/10.1017/S0007114512005934

Acknowledgements

The contribution by Cecilia Nälsén with the dietary analyses and assistance during the study is gratefully acknowledged. The contribution of all the other participants in the KANWU study from Kuopio, Aarhus, Naples and Wollongong in designing and performing the main multicentre study is also warmly acknowledged. The present study was not supported by any external funds. B. V. and I.-B. G. designed the research; B. V., I.-B. G. and S. T. conducted the research; L. B. conducted the statistical analyses; all authors took part in the writing of the manuscript; B. V. had primary responsibility for the final content. None of the authors has declared any conflicts of interest in relation to the present paper and all listed authors have contributed to and seen and approved the manuscript as submitted.

References

1Schaefer, EJ (2002) Lipoproteins, nutrition, and heart disease. Am J Clin Nutr 75, 191212.Google Scholar
2Feskens, EJ (2001) Can diabetes be prevented by vegetable fat? Diabetes Care 24, 15171518.Google Scholar
3Arab, L (2003) Biomarkers of fat and fatty acid intake. J Nutr 133, Suppl. 3, 925S932S.CrossRefGoogle ScholarPubMed
4Baylin, A & Campos, H (2006) The use of fatty acid biomarkers to reflect dietary intake. Curr Opin Lipidol 17, 2227.CrossRefGoogle ScholarPubMed
5Nakamura, MT & Nara, TY (2004) Structure, function, and dietary regulation of Delta6, Delta5, and Delta9-desaturase. Annu Rev Nutr 24, 345376.Google Scholar
6Ntambi, JM & Miyazaki, M (2004) Regulation of stearoyl-CoA desaturases and role in metabolism. Prog Lipid Res 43, 91104.Google Scholar
7Collins, JM, Neville, MJ, Hoppa, MB, et al. (2010) De novo lipogenesis and stearoyl-CoA desaturase are coordinately regulated in the human adipocyte and protect against palmitate-induced cell injury. J Biol Chem 285, 60446052.CrossRefGoogle ScholarPubMed
8Peter, A, Weigert, C, Staiger, H, et al. (2009) Individual stearoyl-CoA desaturase 1 expression modulates endoplasmatic reticulum stress and inflammation in human myotubes and is associated with skeletal muscle lipid storage and insulin sensitivity in vivo. Diabetes 58, 17571765.Google Scholar
9Pan, DA, Lilloja, S, Milner, MR, et al. (1995) Skeletal muscle membrane lipid composition is related to adiposity and insulin action. J Clin Invest 96, 28022808.Google Scholar
10Murakami, K, Sasaki, S, Takahashi, Y, et al. (2008) Lower estimates of δ-5 desaturase and elongase activity are related to adverse profiles for several metabolic risk factors in young Japanese women. Nutr Res 28, 816824.CrossRefGoogle ScholarPubMed
11Warensjö, E, Rosell, M, Hellenius, M-L, et al. (2009) Associations between estimated fatty acid desaturase activities in serum lipids and adipose tissue in humans: links to obesity and insulin resistance. Lipids Health Dis 8, 37.CrossRefGoogle ScholarPubMed
12Paillard, F, Catheline, D, Duff, FL, et al. (2008) Plasma palmitoleic acid, a product of stearoyl-CoA desaturase activity, is an independent marker of triglyceridemia and abdominal adiposity. Nutr Metab Cardiovasc Dis 18, 436440.Google Scholar
13Warensjö, E, Riserus, U & Vessby, B (2005) Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Diabetologia 48, 19992005.CrossRefGoogle ScholarPubMed
14Risérus, U, Ärnlöv, J & Berglund, L (2007) Long-term predictors of insulin resistance. Role of lifestyle and metabolic factors in middle-aged men. Diabetes Care 30, 29282933.CrossRefGoogle ScholarPubMed
15Warensjö, E, Sundström, J, Vessby, B, et al. (2008) Markers of dietary fat quality and fatty acid desaturation as predictors of total and cardiovascular mortality: a population based study. Am J Clin Nutr 88, 203209.CrossRefGoogle Scholar
16Miyazaki, M, Man, WC & Ntambi, JM (2001) Targeted disruption of stearoyl-CoA desaturase 1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid. J Nutr 131, 22602268.CrossRefGoogle ScholarPubMed
17Ntambi, JM, Miyazaki, M, Stoehr, JP, et al. (2002) Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci U S A 99, 1148211486.CrossRefGoogle ScholarPubMed
18Attie, AD, Krauss, RM, Gray-Keller, MP, et al. (2002) Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res 43, 18991907.CrossRefGoogle ScholarPubMed
19Gutierrez-Juarez, R, Pocai, A, Mulas, C, et al. (2006) Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J Clin Invest 116, 16861695.Google Scholar
20Chu, K, Miyazaki, M, Man, WC, et al. (2006) Stearoyl-coenzyme A desaturase deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X activation. Mol Cell Biol 26, 67866798.Google Scholar
21Riserus, U, Tan, GD, Fielding, BA, et al. (2005) Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma. Diabetes 54, 13791384.CrossRefGoogle ScholarPubMed
22Sjogren, P, Sierra-Johnson, J, Gertow, K, et al. (2009) Fatty acid desaturases in human adipose tissue: relationships between gene expression, desaturation indexes and insulin resistance. Diabetologia 51, 328335.CrossRefGoogle Scholar
23Peter, A, Cegan, A, Wagner, S, et al. (2009) Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid rations. Clin Chem 55, 21132120.Google Scholar
24Peter, A, Cegan, A, Wagner, S, et al. (2011) Relationships between hepatic stearoyl-CoA desaturase-1 activity and mRNA expression with liver fat content in humans. Am J Physiol Endocrinol Metab 300, E321E326.Google Scholar
25Hodson, L & Fielding, B (2013) Stearoyl CoA desaturase: rogue or innocent bystander? Prog Lipid Res 52, 1542.Google Scholar
26Martinelli, N, Girelli, D, Malerba, G, et al. (2008) FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. Am J Clin Nutr 88, 941949.Google Scholar
27Malerba, G, Schaeffer, L, Xumerle, L, et al. (2008) SNPs of the FADS gene cluster are associated with polyunsaturated fatty acids in a cohort of patients with cardiovascular disease. Lipids 43, 289299.CrossRefGoogle Scholar
28Merino, DM, Johnston, H, Clarke, S, et al. (2011) Polymorphisms in Fads1 and Fads2 alter desaturase activity in young Caucasian and Asian adults. Mol Genet Metab 103, 171178.CrossRefGoogle ScholarPubMed
29Zietemann, V, Kröger, J, Enzenbach, C, et al. (2010) Genetic variation of the FADs1 FADs2 gene cluster and n-6 PUFA composition in erythrocyte membranes in the European Prospective Investigation into Cancer and Nutrition-Potsdam study. Br J Nutr 104, 17481759.CrossRefGoogle ScholarPubMed
30Vessby, B, Uusitupa, M, Hermansen, K, et al. (2001) Substituting dietary saturated fat for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU study. Diabetologia 44, 312319.Google Scholar
31Bergstrom, J (1962) Muscle electrolytes in man. Scand J Clin Lab Invest 14, Suppl. 68.Google Scholar
32Boberg, M, Croon, L-B, Gustafsson, I-B, et al. (1985) Platelet fatty acid composition in relation to fatty acid composition in plasma and to serum lipoprotein lipids in healthy subjects with special reference to the linoleic acid pathway. Clin Sci (Lond) 68, 581587.CrossRefGoogle Scholar
33Mauvoisin, D & Mounier, C (2011) Hormonal and nutritional regulation of SCD1 gene expression. Biochimie 93, 7886.CrossRefGoogle ScholarPubMed
34Hellerstein, MK (1999) De novo lipogenesis in humans: metabolic and regulatory aspects. Eur J Clin Nutr 53, Suppl. 1, S53S65.CrossRefGoogle ScholarPubMed
35Hudgins, LC, Hellerstein, MK, Seidman, CE, et al. (2000) Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects. J Lipid Res 41, 595604.Google Scholar
36Parks, EJ (2007) Dietary carbohydrate's effect on lipogenesis and the relationship of lipogenesis to blood insulin and glucose concentrations. Br J Nutr 87, Suppl. 2, S247S253.Google Scholar
37Maguire, LS, OÇSullivan, SM, Galvin, K, et al. (2004) Fatty acid profile, tocopherol, squalene and phytosterol content of walnuts, almonds, peanuts, hazelnuts and the macademia nut. Int J Food Sci Nutr 55, 171178.CrossRefGoogle Scholar
38Bené, H, Lasky, D & Ntambi, JM (2001) Cloning and characterization of the human stearoyl-CoA desaturase gene promoter: transcriptional activation by sterol regulatory element binding protein and repression by polyunsaturated fatty acids and cholesterol. Biochem Biophys Res Commun 284, 11941198.Google Scholar
39Sampath, H, Miyazaki, M, Dobrzyn, A, et al. (2007) Stearoyl-CoA desaturase-1 mediates the pro-lipogenic effects of dietary fat. J Biol Chem 282, 24832493.CrossRefGoogle Scholar
40Sampath, H & Ntambi, JM (2005) Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu Rev Nutr 25, 317340.Google Scholar
41Pinnamaneni, SK, Southgate, RJ, Febbraio, MA, et al. (2006) Stearoyl CoA desaturase 1 is elevated in obesity but protects against fatty acid-induced skeletal muscle insulin resistance in vitro. Diabetologia 49, 30273037.Google Scholar
42Lin, J, Yang, R, Tarr, PT, et al. (2005) Hyperlipidemic effects of dietary saturated fats mediated through PGC-1 beta coactivation of SREBP. Cell 120, 261273.Google Scholar
43Kim, H-J, Miyazaki, M & Ntambi, JM (2002) Dietary cholesterol opposes PUFA-mediated repression of the stearoyl-CoA desaturase-1 gene by SREBP-1 independent mechanism. J Lipid Res 43, 17501757.CrossRefGoogle ScholarPubMed
44Pawlosky, RJ, Hibbeln, JR, Lin, Y, et al. (2003) Effects of beef- and fish-based diets on the kinetics of n-3 fatty acid metabolism in human subjects. Am J Clin Nutr 77, 565572.Google Scholar
45Hussein, N, Ah-Sing, E, Wilkinson, P, et al. (2005) Long-chain conversion of (13C)linoleic acid and α-linolenic acid in response to marked changes in their dietary intake in men. J Lipid Res 46, 269280.Google Scholar
46Karpe, F & Hodson, L (2008) Caution on the interpretation of plasma fatty acid composition as a proxy marker for SCD1 activity: particular implications for using the 16:1/16:0 ratio in QTL studies involving hyperlipdemic patients. Arterioscler Thromb Vasc Biol 28, e152.CrossRefGoogle Scholar
47Bjermo, H, Iggman, D, Kullberg, J, et al. (2012) Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr 95, 10031012.CrossRefGoogle ScholarPubMed
48Stefan, N, Kantarzis, K, Celebi, N, et al. (2010) Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans. Diabetes Care 33, 405407.Google Scholar
49Hudgins, LC, Hellerstein, M, Seidman, C, et al. (1996) Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet. J Clin Invest 97, 20812091.Google Scholar
50Chong, MF-F, Hodson, L, Bickerton, AS, et al. (2008) Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 d of high-carbohydrate feeding. Am J Clin Nutr 87, 817823.Google Scholar
Figure 0

Table 1 Clinical characteristics of the participants (Mean values and standard deviations, n 34)

Figure 1

Table 2 Fatty acid desaturase activities estimated from the serum cholesteryl ester (CE) and phospholipid (PL) fatty acid compositions in subjects randomised to the SFA (n 17) and MUFA (n 17) diets, respectively* (Mean values and standard deviations)

Figure 2

Table 3 Fatty acid desaturase activities estimated from the serum cholesteryl ester (CE) and phospholipid (PL) fatty acid compositions in subjects randomised to supplementation with Pikasol (3·4 g/d) (n 17) or placebo (n 17), respectively* (Mean values and standard deviations)

Figure 3

Table 4 Indices of fatty acid desaturase activities in skeletal muscle phospholipids (PL) and TAG after the change in dietary fat type (SFA v. MUFA) and supplementation with Pikasol (3·4 g/d) or placebo, respectively* (Mean values and standard deviations)

Supplementary material: File

Vessby Supplementary Material

Appendix

Download Vessby Supplementary Material(File)
File 47.1 KB